Testing a new pancreatic enzyme treatment for cystic fibrosis patients

This trial is testing a new medication called ANG003, which is a pancreatic enzyme replacement therapy designed to help people with cystic fibrosis whose pancreas doesn't produce enough digestive enzymes. Researchers want to see if this medication works just as well as Creon, the current standard enzyme treatment that many CF patients already use. The study will compare how well the new medication helps your body digest food compared to Creon.

People with cystic fibrosis often struggle with pancreatic insufficiency, meaning their pancreas doesn't make enough enzymes to properly digest food. This can lead to poor nutrition and digestive problems. Researchers are developing this medication as a potential new option that might work just as well as—or better than—current treatments.